Louisiana State University Health Sciences Center Shreveport
Trial Pipeline
Effect of Rapid Heat Stress on Firefighters Musculoskeletal Injury Risk
NCT06442956
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
NCT06482554
Gluteal Activation Plus Movement Retraining
NCT07293039
The PRIME-CRC Trial to Promote CRC Screening in Rural Communities
NCT04313114
Plasma Hydrogen Sulfide as a Biomarker for Alzheimer's Disease and Related Dementias
NCT05060848
Impact of the Wingate Test on Post-activation Potentiation
NCT06779409
Optimization of Blood Levels of 25(OH)-Vitamin D in African Americans
NCT04939792
Curcumin Biomarker Trial in Head and Neck Cancer
NCT01160302
Early Detection of Mild Cognitive Impairment in Individual Patients
NCT00243451
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 1 |
Therapeutic Areas
What the Pipeline for Louisiana State University Health Sciences Center Shreveport Shows
According to the ClinicalTrials.gov registry, Louisiana State University Health Sciences Center Shreveport is linked to 9 US clinical trials across every stage of research activity. Of those, 2 studies are currently recruiting — about 22% of the sponsor's indexed portfolio — and 4 are already marked complete, representing roughly 44% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Louisiana State University Health Sciences Center Shreveport reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 2 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Louisiana State University Health Sciences Center Shreveport is Muscle Activation with 1 linked trial, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.